Abstract 959P
Background
The efficacy of immune checkpoint inhibitors combined with antivascular agents has been demonstrated in a variety of solid tumors including HCC. Suvemcitug, selectively binds to and blocks VEGFA from binding to VEGFR1 and 2, thereby inhibiting its activities and preventing tumour angiogenesis and ultimately suppressing tumour growth and metastasis. Envafolimab is a humanized single-domain anti- PD-L1 antibody which is administered subcutaneously (SC). This study aims to assess the efficacy and safety of the combination of suvemcitug and envafolimab as second-line or later therapy in patients (pts) with advanced HCC.
Methods
This was an open-label, multi-cohort, multicenter, phase II trial conducted in China. In Cohort B, eligible pts had received at least one prior line of treatment for HCC and were treated with suvemcitug (2 mg/kg IV Q3W) plus envafolimab (300 mg SC Q3W) until disease progression or unacceptable toxicity was observed. The primary endpoint was objective response rate (ORR) assessed by investigator review using RECIST v1.1. Secondary endpoints included disease control rate (DCR), duration of overall response (DoR), progression-free survival (PFS) and safety.
Results
As of March 31,2023, a total of 20 patients were treated with envafolimab and suvemcitug. 80.0% pts (16/20) received one prior therapy and 40.0% pts (8/20) were prior treated with immunotherapy. After a median follow up of 7.4 (5.0, 9.3) months, in 18 efficacy-evaluable patients, the confirmed ORR was 11.1% (2/18), and the DCR was 72.2% (13/18). The median PFS was 4.3 (95% CI 1.4-8.1) months. The most common grade 3 or greater treatment-related adverse events were proteinuria (20.0%,4/20), hypertension (5%,1/20), platelet count decreased (5%, 1/20), blood bilirubin increased (5%, 1/20), γ-glutamyl transferase increased, oesophagitis (5%, 1/20),and oral ulcer (5%, 1/20). No treatment-related death was reported.
Conclusions
The use of envafolimab and suvemcitug did not result in increased safety concerns. Suvemcitug and envafolimab demonstrated antitumor activity and manageable safety profile in pts with prior treated HCC. Research Sponsor: Shanghai Xianxiang Medical Technology Co., Ltd. and 3D Medicines Inc.
Clinical trial identification
NCT05148195.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Xianxiang Medical Technology Co., Ltd. and 3D Medicines Inc.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18